Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Longeveron

Recent news which mentions Longeveron

Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results
Tickers LGVN
Tags Market News Partner Content LGVN
From Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Tickers LGVN
Tags News LGVN Biotech
From Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Tickers LGVN
Tags Partner Content LGVN News
From Benzinga
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
Tickers LGVN
Tags Biotech LGVN Partner Content
From Benzinga
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
Tickers LGVN
Tags Longeveron Penny Stocks Benzinga
From Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
Tickers AMGN LGVN MRNA
Tags Longeveron General Health Care
From Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Tickers ABOS BIIB LGVN TLSA
Tags Partner Content General ABOS
From Benzinga
Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases
Tickers LGVN
Tags Interview Market News Biotech
From Benzinga
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
Tickers AMGN LGVN LLY
Tags AMGN Benzinga LLY
From Benzinga
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS
Tickers LGVN
Tags Market News Interview LGVN
From Benzinga
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes?
Tickers LGVN
Tags General Benzinga Penny Stocks
From Benzinga
Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty
Tickers LGVN
Tags Penny Stocks Benzinga Market News
From Benzinga
LGVN: Updating Model Following 2Q Results
Tags Benzinga Longeveron Market News
From Benzinga
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
Tickers ALZN BIIB LGVN SLDB
Tags Partner Content SLDB General
From Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
Tickers ANVS LGVN LLY TECH
Tags Partner Content Biotech ANVS
From Benzinga
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
Tickers BMY LGVN
Tags Market News Partner Content LGVN
From Benzinga
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Tickers LGVN SAVA STAB
Tags Partner Content General STAB
From Benzinga
Longeveron Partners With US Department Of Veterans Affairs For Its Phase 2 Alzheimer's Trial
Tickers LGVN
Tags Longeveron General Benzinga
From Benzinga
Healthspan, Not Lifespan Should Be the Focus of Anti-Aging Research, Says Longeveron
Tickers AMZN LGVN UBX
Tags Health Care General Longeveron
From Benzinga
Longeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress
Tickers LGVN
Tags Press Releases Biotech LGVN
From Benzinga
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
Tickers LGVN
Tags General Longeveron LGVN
From Benzinga
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
Tickers LGVN
Tags Partner Content Market News Biotech
From Benzinga
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
Tickers LGVN
Tags Longeveron Health Care General
From Benzinga
Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron
Tickers JNJ LGVN MRN PFE
Tags JNJ General Partner Content
From Benzinga
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
Tickers LGVN
Tags Biotech LGVN Partner Content
From Benzinga
Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval
Tags General Health Care Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.